FXDvsIBRN
FIRST TRUST CONSUMER DISCRETIONARY ALPHADEX FUND against iShares Neuroscience and Healthcare ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| FXD | IBRN | |
|---|---|---|
| Expense ratio | — | 0.47% |
| Assets | $1.5B | $6640.17T |
| Net flow, 1 month | — | +$94K |
| Net flow, 1 year | — | +$2M |
| Return, YTD | -5.5% | +0.7% |
| Return, 1 year | -5.6% | +18.6% |
| Avg daily volume | 9K | 2K |
| Holdings | 122 | 54 |
| Listed | Nov 5, 2023 | Aug 24, 2022 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS